Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease: Effect of Baseline Amikacin and Clarithromycin Susceptibility on Culture Conversion

被引：0
|
作者：
Winthrop, K. L. [1 ]
Flume, P. A. [2 ,3 ]
Thomson, R. [4 ]
Brown-Elliott, B. A. [5 ]
Wallace, R. J., Jr. [5 ]
Griffith, D. E. [6 ]
Pennings, L. J. [7 ]
Coulter, C. [8 ]
Syrmis, M. [8 ]
Pandey, S. [8 ]
Yuen, D. [9 ]
Mange, K. [9 ]
van Ingen, J. [7 ]
机构：
[1] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA
[2] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA
[3] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA
[4] Univ Queensland, Gallipoli Med Res Inst, Brisbane, Qld, Australia
[5] Univ Texas Hlth Sci Ctr Tyler, Mycobacteria Nocardia Lab, Tyler, TX USA
[6] Univ Texas Hlth Sci Ctr Tyler, Tyler, TX USA
[7] Radboud Univ Nijmegen Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
[8] Pathol Queensland, Queensland Mycobacterium Reference Lab, Brisbane, Qld, Australia
[9] Insmed Inc, Bridgewater, NJ USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4494
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease (vol 46, pg 277, 2021)
    Rubino, Christopher M.
    Onufrak, Nikolas J.
    van Ingen, Jakko
    Griffith, David E.
    Bhavnani, Sujata M.
    Yuen, Dayton W.
    Mange, Kevin C.
    Winthrop, Kevin L.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2021, 46 (04) : 573 - 574
  • [42] Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
    Christopher M. Rubino
    Nikolas J. Onufrak
    Jakko van Ingen
    David E. Griffith
    Sujata M. Bhavnani
    Dayton W. Yuen
    Kevin C. Mange
    Kevin L. Winthrop
    European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46 : 573 - 574
  • [43] Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study
    Morimoto, Kozo
    Nonaka, Mizu
    Yamazaki, Yoshitaka
    Nakagawa, Taku
    Takasaki, Jin
    Tsuyuguchi, Kazunari
    Kitada, Seigo
    Jumadilova, Zhanna
    Yuen, Dayton W.
    Ciesielska, Monika
    Hasegawa, Naoki
    RESPIRATORY INVESTIGATION, 2024, 62 (02) : 284 - 290
  • [44] SURVEY ON USE AND PERCEPTION OF AMIKACIN FOR TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE IN THE UK
    Obradovic, M.
    Van der Laan, R.
    Hale, J.
    Gerden, E.
    Musson, L.
    THORAX, 2021, 76 : A177 - A178
  • [45] Predictive risk factors of treatment-refractory Mycobacterium avium complex lung disease
    Saito, Takahiko
    Aono, Yuya
    Kono, Masato
    Sugiura, Takuma
    Higasa, Misato
    Katsumata, Mineo
    Miwa, Hideki
    Miki, Yoshihiro
    Hashimoto, Dai
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [46] Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease
    Kim, Bo-Guen
    Kim, Hojoong
    Kwon, O. Jung
    Huh, Hee Jae
    Lee, Nam Yong
    Baek, Sun-Young
    Sohn, Insuk
    Jhun, Byung Woo
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 12
  • [47] Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)
    Olivier, Kenneth N.
    Eagle, Gina
    McGinnis, John P., II
    Micioni, Liza
    Brown-Elliott, Barbara A.
    Wallace, Richard J., Jr.
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [48] A Randomized, Double-blind Trial of Amikacin Liposome Inhalation Suspension in Adults With Newly Diagnosed or Recurrent Mycobacterium Avium Complex Lung Disease to Validate Patient-reported Outcome Instruments and Assess Microbiological Outcomes of Treatment: The ARISE Study
    Daley, C. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [49] A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC)
    Griffith, David
    Flume, Patrick
    Winthrop, Kevin
    Thomson, Rachel
    Wagner, Dirk
    Van Ingen, Jakko
    Micioni, Liza
    McGinnis, John P., II
    Fernandez, Carlos
    Eagle, Gina
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [50] TREATMENT PATTERNS AND HEALTH CARE RESOURCE UTILIZATION AMONG PATIENTS WITH POTENTIALLY TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE IN THE UNITED STATES
    Winthrop, Kevin L.
    Wang, Ping
    Lucci, Matthew
    Welch, Emily
    Shah, Bonny
    Hassan, Mariam
    CHEST, 2023, 164 (04) : 768A - 769A
12345